<DOC>
	<DOC>NCT00723931</DOC>
	<brief_summary>Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with chronic hepatitis C are generally treated. The purpose of this surveillance is to evaluate the postmarketing safety and efficacy of PegIntron Injection under actual conditions of use and to examine adverse events, serious adverse events, and adverse drug reactions.</brief_summary>
	<brief_title>PegIntron Injection Surveillance Plan (Study P04123)</brief_title>
	<detailed_description>The investigator will record continuously from the first patient since the day of contract to the numbers of patients of contract based on Pegintron approval.</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants with chronic hepatitis C treated with peginterferon alfa2b. Signed written contract.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>